A selective CD28 antagonist and rapamycin synergise to protect against spontaneous autoimmune diabetes in NOD mice

Novel CD28 antagonist mPEG PV1-Fab’ mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production

(2017) Pedro Henrique Papotto et al.   PLoS One

CD28 Costimulation: From Mechanism to Therapy

(2016) Jonathan H. Esensten et al.   IMMUNITY

First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28

(2016) Nicolas Poirier et al.   JOURNAL OF IMMUNOLOGY

Clinical efficacy of a new CD28-targeting antagonist of T cell co-stimulation in a non-human primate model of collagen-induced arthritis

(2015) M. P. M. Vierboom et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Selective Blockade of CD28-Mediated T Cell Costimulation Protects Rhesus Monkeys against Acute Fatal Experimental Autoimmune Encephalomyelitis

(2015) Krista G. Haanstra et al.   JOURNAL OF IMMUNOLOGY

The Allo- and Viral-Specific Immunosuppressive Effect of Belatacept, but Not Tacrolimus, Attenuates With Progressive T Cell Maturation

(2014) H. Xu et al.   AMERICAN JOURNAL OF TRANSPLANTATION

FR104, an Antagonist Anti-CD28 Monovalent Fab' Antibody, Prevents Alloimmunization and Allows Calcineurin Inhibitor Minimization in Nonhuman Primate Renal Allograft

(2014) N. Poirier et al.   AMERICAN JOURNAL OF TRANSPLANTATION

PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+T cells

(2012) David K. Finlay et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity

(2012) D. W. Lamming et al.   SCIENCE

Protein Kinase B Controls Transcriptional Programs that Direct Cytotoxic T Cell Fate but Is Dispensable for T Cell Metabolism

(2011) Andrew N. Macintyre et al.   IMMUNITY

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue

(2010) V. P. Houde et al.   DIABETES

Inducing CTLA-4-Dependent Immune Regulation by Selective CD28 Blockade Promotes Regulatory T Cells in Organ Transplantation

(2010) N. Poirier et al.   Science Translational Medicine